plustherapeutics.com (PSTV) - Profit After Payment of Taxes

Plus Therapeutics, Inc. (PSTV) is developing innovative Rhenium-186 radiotherapy to combat brain and breast tumors. Experienced management is effectively securing government grants to expand scientific potential. However, high cost of capital and the logistical complexity of isotopes create significant barriers. The company's cash profit on this chart demonstrates current margins, where the final parameter equals -0.02.

PSTV (Cytori Therapeutics) Net Profit history from 07/04/2022 to 08/03/2026

Analytical breakdowns and data insights for company plustherapeutics.com (PSTV)

- current quotes and average value forecast:

Market Chart Plus Therapeutics|PSTV - Consensus Target

- market capitalization indicators:

Market Value PSTV|PSTV - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Accounting Value of a Share Plus Therapeutics|PSTV - Book Capitalization|Market Cap to Net Assets Ratio plustherapeutics.com|PSTV - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

PSTV - Company Net Income

Fundamental valuation:PSTV, Cytori Therapeutics

Manufactured product of Cytori Therapeutics

This indicator measures daily net income dynamics to assess the business's capacity for long-term expansion, where growth confirms market capture and extremes signal the risk of overpayment. When analyzing the financial results of Plus Therapeutics, Inc. (PSTV), it is important to note that outsourcing isotope production minimizes fixed costs for Plus Therapeutics, Inc. (PSTV), ensuring the asset's stability even amidst high R&D expenses.

Direct competitors